News and Announcements
Punakaiki Fund: $35 million in Assets, 670 shareholders, IRR 36%
- Published January 10, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Family Zone (FZO) purchasing Linewize
- OneLogin purchasing assets of ThisData
- $7.8 million raised, for total of $23.5 million so far
- Assets valued at $32.3 Million (PDS for December 2017 Offer) December offer raised $3.44 million at $21 per share
- 20 investments, 670 shareholders, Internal IRR of 36% (as at PDS)
Our strategy of investing in high quality, high-growth companies in New Zealand is working well. We were pleased when two of our investments, Linewize and ThisData (which was less material), were sold to trade buyers over the last few months. Each was sold for well over two times the amount that each was previously valued at in our accounts.
The sale of our Linewize shares was a genuine surprise, with the deal moving from initial offer to signed agreement in just a month and a day. We now own 3.81 million shares (including 1.9 million performance shares) in ASX-listed Family Zone. We are happy for the founders and pleased with our return on our $1 million investment, with 60% of that investment placed just one year ago.
We closed a regulated (public) offer to NZ shareholders in December 2017, raising $3.45 million at $21 per share, and based on a share price basis of $21.97 per share, with an investor net asset value of $21.31 per share.
We are contemplating an offer to larger and offshore investors in February/March 2018.
About Punakaiki Fund
Punakaiki Fund is New Zealand’s premier investor in high growth companies, with 18 investments and NZ$18 million of assets.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
